Ustekinumab Safety in Psoriasis, Psoriatic Arthritis, and Crohn’s Disease: An Integrated Analysis of Phase II/III Clinical Development Programs

[1]  S. Ng,et al.  Management of Patients With Crohn’s Disease and Ulcerative Colitis During the Coronavirus Disease-2019 Pandemic: Results of an International Meeting , 2020, Gastroenterology.

[2]  L. Conti,et al.  Preventing Infections by Encapsulated Bacteria Through Vaccine Prophylaxis in Inflammatory Bowel Disease , 2020, Frontiers in Immunology.

[3]  W. Marut,et al.  Novel insights into dendritic cells in the pathogenesis of systemic sclerosis , 2020, Clinical and experimental immunology.

[4]  H. Einwächter.  Current Concepts of Pharmacotherapy in Crohn’s Disease , 2019, Visceral Medicine.

[5]  C. Ahn,et al.  Asymptomatic Crohn’s disease identified in a patient being treated with secukinumab: A case report , 2019, SAGE open medical case reports.

[6]  M. Lebwohl,et al.  Psoriasis: Which therapy for which patient: Psoriasis comorbidities and preferred systemic agents. , 2019, Journal of the American Academy of Dermatology.

[7]  M. Lebwohl,et al.  Psoriasis: Which therapy for which patient: Focus on special populations and chronic infections. , 2018, Journal of the American Academy of Dermatology.

[8]  J. Gelfand.  Commentary: Does biologic treatment of psoriasis lower the risk of cardiovascular events and mortality?: A critical question that we are only just beginning to answer. , 2018, Journal of the American Academy of Dermatology.

[9]  M. Lebwohl,et al.  Risk of malignancy with systemic psoriasis treatment in the Psoriasis Longitudinal Assessment Registry , 2017, Journal of the American Academy of Dermatology.

[10]  E. Loftus,et al.  Comparison of Rates of Active Tuberculosis Infection in the Phase 2 and 3 Clinical Trial Programs for Anti-IL12/23 and Anti-TNFS , 2017 .

[11]  L. Eder,et al.  Risk of Cardiovascular Morbidity in Patients With Psoriatic Arthritis: A Meta‐Analysis of Observational Studies , 2017, Arthritis care & research.

[12]  A. Gottlieb,et al.  THU0434 Serious Infections in Psoriasis Patients with Psoriatic Arthritis in The Psoriasis Longitudinal Assessment and Registry Study , 2016 .

[13]  A. Gottlieb,et al.  THU0450 All-Cause Mortality and Malignancies in Psoriasis Patients with Psoriatic Arthritis in The Psoriasis Longitudinal Assessment and Registry Study , 2016 .

[14]  P. Rutgeerts,et al.  Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease. , 2016, The New England journal of medicine.

[15]  A. Gottlieb,et al.  Maintenance of Clinical Efficacy and Radiographic Benefit Through Two Years of Ustekinumab Therapy in Patients With Active Psoriatic Arthritis: Results From a Randomized, Placebo‐Controlled Phase III Trial , 2015, Arthritis care & research.

[16]  A. Burden,et al.  Differential Drug Survival of Biologic Therapies for the Treatment of Psoriasis: A Prospective Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). , 2015, The Journal of investigative dermatology.

[17]  A. Gottlieb,et al.  Safety Surveillance for Ustekinumab and Other Psoriasis Treatments From the Psoriasis Longitudinal Assessment and Registry (PSOLAR). , 2015, Journal of drugs in dermatology : JDD.

[18]  J. Koo,et al.  Evidence-based adverse effects of biologic agents in the treatment of moderate-to-severe psoriasis: Providing clarity to an opaque topic , 2015, The Journal of dermatological treatment.

[19]  L. Skov,et al.  Comparison of long‐term drug survival and safety of biologic agents in patients with psoriasis vulgaris , 2015, The British journal of dermatology.

[20]  A. Burden,et al.  Persistence with biologic therapies for the treatment of moderate to severe psoriasis: a prospective observational study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). , 2014 .

[21]  A. Gottlieb,et al.  Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, , 2014, Annals of the rheumatic diseases.

[22]  A. Kimball,et al.  Long‐term efficacy of ustekinumab in patients with moderate‐to‐severe psoriasis treated for up to 5 years in the PHOENIX 1 study , 2013, Journal of the European Academy of Dermatology and Venereology : JEADV.

[23]  A. Gottlieb,et al.  Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial , 2013, The Lancet.

[24]  Kristin Stephens,et al.  Vedolizumab as induction and maintenance therapy for Crohn's disease. , 2013, The New England journal of medicine.

[25]  B. Strober,et al.  Long‐term safety of ustekinumab in patients with moderate‐to‐severe psoriasis: final results from 5 years of follow‐up , 2013, The British journal of dermatology.

[26]  G. Greenberg,et al.  Ustekinumab induction and maintenance therapy in refractory Crohn's disease. , 2012, The New England journal of medicine.

[27]  B. Strober,et al.  PSOLAR: design, utility, and preliminary results of a prospective, international, disease-based registry of patients with psoriasis who are receiving, or are candidates for, conventional systemic treatments or biologic agents. , 2012, Journal of drugs in dermatology : JDD.

[28]  J. Manson,et al.  Psoriasis and risk of nonfatal cardiovascular disease in U.S. women: a cohort study , 2012, The British journal of dermatology.

[29]  B. Scallon,et al.  Discovery and mechanism of ustekinumab , 2011, mAbs.

[30]  P. Saltiel,et al.  Reversible posterior leukoencephalopathy syndrome in a patient treated with ustekinumab: case report and review of the literature. , 2011, Archives of Dermatology.

[31]  D. Veale,et al.  Cardiovascular Disease and Risk Factors in Patients with Psoriasis and Psoriatic Arthritis , 2010, The Journal of Rheumatology.

[32]  B. Strober,et al.  Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. , 2010, The New England journal of medicine.

[33]  J. Weinberg.  Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial , 2010 .

[34]  A. Gottlieb,et al.  Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial , 2009, The Lancet.

[35]  Ustekinumab: new drug. Suspicion of carcinogenicity: too great a risk for psoriasis patients. , 2009, Prescrire international.

[36]  P. Rutgeerts,et al.  A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease. , 2008, Gastroenterology.

[37]  M. Lebwohl,et al.  Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2) , 2008, The Lancet.

[38]  A. Kimball,et al.  Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1) , 2008, The Lancet.

[39]  R. Kastelein,et al.  Swords into plowshares: IL-23 repurposes tumor immune surveillance. , 2007, Trends in immunology.

[40]  M. Lebwohl,et al.  A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. , 2007, The New England journal of medicine.

[41]  Urso FORTE. Urso.  HIGHLIGHTS OF PRESCRIBING INFORMATION , 2007 .

[42]  P. Cortelli,et al.  Which therapy for which patient? , 2006, Neurological Sciences.